

COMPANY FACT SHEET



Optiscan Imaging (ASX: OIL) is a global leader in digital microscopic imaging, offering live sub-cellular imaging solutions in the palm of your hand.


Investment highlights

- Unique, Patent protected technology
- Platform technology with broad applications
- Clinically proven in multiple settings
- International exposure and expanding distribution network
- Planned product and revenue stream diversification
- Significant investment into R&D, clinical trials, and innovation
- Debt-free balance sheet

Market need and commercial opportunity

- Technology enables instantaneous clinical decision making, leading to earlier detection, diagnosis and treatment of cancer
- Disruptive: Biopsy-free, slide-free and non-destructive, unlike traditional pathology
- Ability to image multiple tissue types and establish a new standard of care in digital pathology and precision surgery

Global estimated number of new cases in 2020¹



Size of US burden of care by cancer type in 2020²

Optiscan Imaging is targeting markets worth over US\$62.4bn for some of the world's most severe cancer problems.

\$24.3bn
Colorectal
Cancer

\$29.8bn
Female Breast
Cancer

\$6.0bn
Oral Cavity
Cancer

\$2.3bn
Cervical Cancer

Market data

ASX code:	OIL
Share price:	A\$0.15
Market cap:	A\$93M
Shares on issue:	619,605,602

Board and Management

Dr. Camile Farah	CEO & Managing Director
Robert Cooke	Chairman
Ron Song	Non-Executive Director
Karen Borg	Non-Executive Director
Sean Gardiner	Non-Executive Director

Contact

Dr. Camile Farah
CEO & Managing Director
E: cfarah@optiscan.com
T: +61 3 9538 3333

1. GLOBOCAN 2020

2. Financial Burden of Cancer Care, US National Institutes of Health